by United Pompe | Jan 18, 2016 | News
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
by United Pompe | Jan 18, 2016 | News
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study
by United Pompe | Jan 18, 2016 | News
January 2008 US Myozyme Supply Update In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in order to ensure uninterrupted treatment for as many patients as possible. Since April, both the...
by United Pompe | Jan 18, 2016 | News
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement
by United Pompe | Jan 18, 2016 | News
October Update on the US Myozyme® Supply